OasisLMS

The EGFR-mutated NSCLC treatment arsenal has become more complex, with a growing number of single-agent and combination options available in the first-line and pretreated settings of metastatic NSCLC with classical EGFR mutations and less common mutations, such as EGFR exon 20 insertion mutations. Expanded therapeutic options are making it more challenging to determine which agent or combination to use in which patients, how to sequence therapies throughout the disease continuum, and how to best manage the unique AEs that can arise with various regimens.

In this PeerView educational activity, based on a recent live virtual symposium, leading experts provide insight on the latest evidence supporting targeted therapies in EGFR-mutated NSCLC. Watch today and learn how to make informed, data-driven clinical decisions, manage care coordination among your multidisciplinary team, and provide the right treatment at the right time for each of your patients.

Enduring Activity Launch Date: 6/18/2025
Enduring Activity Expiration Date: 6/18/2026

This activity has been designed to meet the educational needs of thoracic oncologists, medical oncologists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with lung cancer.

Upon completion of this educational activity, participants should be able to: 

• Evaluate the latest evidence and guideline recommendations supporting the use of different EGFR-targeted therapies, combinations, and formulations in EGFR-mutated NSCLC
• Develop individualized treatment plans with EGFR-targeted agents and combinations for patients with EGFR-mutated NSCLC that consider biomarker testing results, clinical evidence, guideline recommendations, formulations and routes of administration, and patient needs and preferences
• Employ team-based strategies to address the practicalities of treatment delivery with EGFR-targeted therapies in EGFR-mutated NSCLC, including patient education, shared decision-making, and prevention/ management of treatment-related AEs

This activity is supported by an educational grant from Johnson & Johnson

Planners:

• Natasha Leighl, MD, MMsc, FRCPC, FASCO | Lung Site Lead, Medical Oncology, Princess Margaret Cancer Centre | Toronto, Canada
• Joshua Sabari, MD | Assistant Professor of Medicine, NYU Langone Health | New York, USA

The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name	Commercial Interest	Role	Level of Participation in the Activity
Natasha Leighl	1. Bayer Corporation; GSK; and Puma Biotechnology, Inc. 2. Amgen; Array BioPharma, Inc.; AstraZeneca; Bayer Corporation; Bristol Myers Squibb; EMD Serono, Inc.; F. Hoffmann-La Roche AG; Guardant Health; Inivata Ltd; Lilly; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; Pfizer; and Takeda Pharmaceutical Company Limited.	1. Consultant/Advisor 2. Grant/Research	Co-Chair/Planner
Joshua Sabari	1. AbbVie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited. 2. Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.	1. Consultant/Advisor 2. Grant/Research	Co-Chair/Planner

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity. 

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below. 

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the live and enduring activity for a maximum of 1 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Associates
The National Commission on Certification of Physician Associates (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

Successful Completion
Sucessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

• 1 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program

It is the CME Activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation. 

Countries that accept ACCME-accredited continuing medical education (CME):

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians. 

Antigua & Barbuda
Regulator: Antigua & Barbuda Medical Council

Austria
Regulator: Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
Regulator: Bahamas Medical Council

Belgium
Regulator: Group of Belgian Professional Unions of Specialist Doctors

Bhutan
Regulator: Medical and Health Professional Council, Royal Government of Bhutan

Canada
Regulator: Royal College of Physicians and Surgeons of Canada Maintenance of Certification Program

Croatia
Regulator: Croatian Medical Chamber

Gambia, The
Regulator: The Medical and Dental Council of the Gambia

Germany
Regulator: State Chambers of Physicians in the 16 federal states (only in-person, live events)

India, State of Punjab
Regulator: Punjab Medical Council

Israel
Regulator: Scientific Council, Israeli Medical Association

Jamaica
Regulator: Medical Council of Jamaica

Kuwait
Regulator: Professional Licensing - Ministry of Health

Malawi
Regulator: Medical Council of Malawi

Netherlands, The
Regulator: Royal Dutch Society of the Promotion of Medicine

Oman
Regulator: Oman Medical Specialty Board

Qatar
Regulator: Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
Regulator: Rwanda Medical & Dental Council

Saudi Arabia
Regulator: Saudi Commission for Health Specialties

Singapore
Regulator: Singapore Medical Council

South Africa
Regulator: Health Professions Council of South Africa

Spain
Regulator: Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
Regulator: Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
Regulator: Swedish Medical Association

Trinidad & Tobago
Regulator: The Trinidad and Tobago Medical Association

Turkey
Regulator: Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
Regulator: Department of Health

United Arab Emirates, Dubai
Regulator: Dubai Health Authority

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Live Activity Credit

To successfully earn credit, participants must complete the activity during the valid credit period that is notes on the title page. Follow these steps to earn CME/CE Credit*

1. Read about the target audience, learning objectives, and author disclosures.
2. Participate in the activity.
3. Complete the activity evaluation to provide feedback for future programs and receive credit.

Enduring Activity Credit

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test. Follow these steps to earn CME/CE credit*:

1. Read about the target audience, learning objectives, and author disclosures.

2. Study the educational content online or print it out, if applicable.
3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.
4. Complete the activity evaluation to provide feedback for future programming and receive credit.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.

If you need assistance with this activity, please email: education@iaslc.org.